Please login to the form below

Not currently logged in
Email:
Password:

INC Research expands infectious diseases team with appointment of Dr Frederick Young

He joins the CRO from ICON, where he served as vice president of strategic programmes

INC Research has appointed ICON's former vice president of strategic programmes Dr Frederick Young as vice president of infectious diseases.

The contract research organisation (CRO) says the addition of Dr Young will support its work in global vaccine development research as well as expanding its infectious diseases team.

"Antibiotics and other antimicrobials have played a critical role in the fight against infectious diseases, but further discovery and evaluation of new treatments is still needed," said Patricia Monteforte, executive vice president and general manager, general medicine, INC Research.

"We've become a leader in infectious diseases research by having a therapeutically-focused team with experience in all stages and disciplines associated with the development of anti-infectives. With the addition of Frederick, INC Research is positioned to expand this therapeutic unit even further with experienced resources to support and advance our customers' research and development."

Prior to his time with ICON, where he worked for nearly four years, Dr Young served at Novartis in a number of roles, including clinical research scientist, executive director, project leader and, most recently, global programme director.

25th April 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics